Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-label Study of T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

NCT05756556 is registered in ClinicalTrials.gov with ImmVira Pharma Co. Ltd as lead sponsor.

NCT NCT05756556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05756556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-label Study of T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
Lead sponsor
ImmVira Pharma Co. Ltd
Phase
Phase 2
Overall status
Suspended
Start date
June 30, 2024
Completion date
January 1, 2027
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, melanoma